Featured News

Periodically, the FDA hosts workshops to help researchers understand exactly what the FDA will be looking for (aka “endpoints”) when evaluating the efficacy of a proposed drug.

We are determined to use every resource at our disposal, including strategic funding of research and advocacy, to help discover and bring to the celiac disease patient community therapeutic alternatives to the gluten-free diet.

The NIH Accelerating Progress in Celiac Disease Workshop is a direct outcome of our advocacy efforts in Washington, DC. CEO Marilyn Geller was invited to speak about what our celiac community needs. Watch her presentation here.

Rep. Betty McCollum (D-MN) and Rep. Steve Stivers (D-OH) announced the formation of the Congressional Celiac Disease Caucus at the 2021 Celiac Disease Foundation Patient Education & Advocacy Summit.

I want to share with you highlights of our advocacy plans for 2021. Our work in Washington, DC, with Congress, with the NIH, FDA, and other agencies, is critical in the pursuit of treatments and a cure for celiac disease.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.

I am thankful for your support, which has allowed the Celiac Disease Foundation to make a meaningful difference in the lives of our celiac community. 

One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s celiac disease patient registry. This month, researchers published three important studies that used iCureCeliac® as the data source.

Securing public and private health insurance coverage of Medical Nutrition Therapy (MNT) for celiac disease patients has been a long-time priority of the Celiac Disease Foundation.

I want to share with you an update of our work in Washington, DC with Congress and NIH to accelerate research for diagnostics, treatments, and a cure for celiac disease.